2026 has been a busy year for pharmaceutical tariff announcements. In April, the Trump administration announced a new pharmaceutical tariff framework for certain imported patented and branded prescription drugs and active pharmaceutical ingredients. Then, on July 21, 2026, the administration announced a separate phased pharmaceutical tariff plan for imported generic drugs, aimed at encouraging drugmakers to move generic manufacturing to the United States. Under the July plan, imported generic drugs will face a 0% pharmaceutical tariff for two years starting August 1, 2026, before the rate increases to 100% in August 2028 and 200% in August 2029.
Below is a high level summary of what has been announced so far, how it differs from earlier tariff signals in 2025, and what can be monitored as more details emerge.
What the 2026 pharmaceutical tariff updates include
On April 2, 2026, the White House announced a new pharmaceutical tariff framework that would apply to certain imported patented prescription drugs and select active pharmaceutical ingredients (APIs). While the headline tariff rate is 100% for branded products, the policy includes a phased start date and several exception pathways that may limit near term disruption.
The April framework was announced under Section 232, which gives the federal government authority to impose import restrictions following a Commerce Department review. Under that framework, implementation begins 120 days after the announcement for certain large manufacturers and 180 days after the announcement for smaller manufacturers and other importers.
In July 2026, tariffs on generic drugs were announced. Implementation details have not been provided for these generic drug imports, including how the pharmaceutical tariffs will be applied or whether drug-specific exemptions will exist. Biosimilars were not specifically included in the July 2026 announcement, and because they are often treated separately from traditional generics, it remains unclear whether future guidance could address them directly.
How the tariff framework works
Scope, applicability, and exemptions
The April 2026 100% pharmaceutical tariff framework applies to patented brand name drugs and certain active pharmaceutical ingredients, while the July 2026 announcement introduced a separate phased tariff timeline for imported generics. The branded pharmaceutical tariffs also outline exceptions for specific orphan drugs and some specialty products that address urgent public health needs, as long as they meet public health standards or are from countries with trade agreements.
Country based tariff rates
Branded pharmaceutical products imported from the European Union, Japan, South Korea, Switzerland, and Liechtenstein are subject to a 15% tariff rate under the current trade agreement. The United Kingdom is effectively exempt, thanks to a recently finalized pharmaceutical trade agreement. Countries without trade agreements face the headline 100% tariff rate, absent other mitigation.
Reduced or avoided tariffs via compliance
The branded pharmaceutical tariffs also outline reduced rate pathways through January 20, 2029, tied to pharma manufacturer company commitments. There is 0% tariff rate for companies that enter into both Most Favored Nation pricing agreements with the U.S. Department of Health and Human Services (HHS) and onshoring agreements with the Department of Commerce. For companies that enter into onshoring agreements with only the Department of Commerce, there is a 20% tariff rate through January 20, 2029.
How this differs from 2025
In September 2025, federal officials signaled a potential 100% tariff on imported brand name pharmaceuticals, which created uncertainty across manufacturers and the pharmacy supply chain. The April 2026 framework is more defined, with a phased start date, clearer exemptions, and described reduced rate pathways tied to company commitments. For employer sponsored plans, that shift matters because it can concentrate exposure in specific drug categories rather than driving immediate, broad changes across the entire benefit. The July 2026 announcement adds another layer by creating a separate phased timeline for imported generics, which could shift longer-term exposure toward high-volume, lower-margin drugs rather than only patented brand name products.
Expected impact of pharmaceutical tariffs
Drug Pricing
Immediate, broad-based price increases from the pharmaceutical tariffs are unlikely in the near term due to existing exemptions, gradual implementation timelines, and available exception pathways. Over time, however, the pharmaceutical tariffs could create upward pricing pressure for certain imported specialty and patented drugs, particularly those manufactured outside countries covered by trade agreements or not aligned with Most Favored Nation pricing frameworks. The July 2026 pharmaceutical tariff timeline could also create longer-term cost pressure for generic drugs, especially given the U.S. reliance on China and India for roughly 80% of active pharmaceutical ingredients.
Supply Chain
PBMs may reassess formularies based on country of manufacture exposure, margin sensitivity, and supply risk. As some manufacturers shift production onshore, plans could see short term supply disruptions, particularly for complex specialty and biologic therapies.
Generic drugs may face additional pressure because they make up about 90% of U.S. prescriptions. Because profit margins are often thin, added costs could force some generic manufacturers to discontinue certain medicines if they cannot absorb them, potentially causing significant supply chain disruptions.
What this signals for pharmacy benefits
Even with exemptions and a phased timeline, the 2026 framework underscores a broader shift: federal trade policy and manufacturing location can increasingly influence the pharmacy benefit, not just through list prices, but through availability, contracting leverage, and formulary decision making.
- Expect uneven impact, not uniform inflation: Exposure will likely cluster in select imported patented and specialty drugs rather than across the full formulary.
- Transparency becomes more valuable: Country of manufacture and supply chain concentration can affect risk, but those details are not always visible in standard plan reporting.
- PBM decision making may move faster: If sourcing affects net cost, PBMs may reassess preferred products and implement formulary changes with more frequency.
- Contract terms matter: Market change provisions, notice requirements, and governance for formulary updates can determine how much control employers retain during disruption.
- Reassessment risk remains: Biosimilars were not included in the July 2026 tariff announcement, but future guidance could still revisit their treatment and materially expand plan exposure.
As pharmaceutical tariffs continue to take shape, employers and benefits consultants will need to stay focused on where exposure may concentrate rather than assuming across-the-board disruption. Monitoring formulary changes, understanding contract protections, and maintaining regular dialogue with PBMs can help plans respond thoughtfully as details evolve. While the current framework limits immediate impact, pharmaceutical tariffs remain a policy lever worth watching closely as pricing, sourcing, and manufacturing strategies continue to shift.
